September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 29, 2014
Med BioGene Reports Financial Results for Q2 2014
August 21, 2014
Med BioGene Responds to Assertions Made by Dissident Shareholder
August 15, 2014
Med BioGene Provides Update and Announces Proposed Financing
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
March 24, 2014
Med BioGene Announces Regulatory Approval of GeneFx® Lung
Med BioGene to Present at BioContact Québec 2006 in Québec City
September 19, 2006
VANCOUVER, BRITISH COLUMBIA – Med BioGene Inc. (TSX Venture: MBI) is pleased to announce that Erinn B. Broshko, Chief Executive Officer, will be presenting at BioContact Québec 2006 ( www.biocontact.qc.ca) in Québec City. BioContact is a biopharmaceutical partnership symposium with over 1200 participants.
The 30 minute presentation will be followed by a question and answer session and will take place on Thursday, October 5, 2006 at 3:30 p.m. at the Château Frontenac.
About Med BioGene
MBI is a biotechnology company with advanced research and development in gene expression technology. MBI is utilizing its expertise in gene expression to identify those genes, known as "biomarkers," which mark the presence of certain cancers and cardiovascular disease.
These biomarkers will be used as an effective tool for disease diagnosis and to unlock innovation in therapeutic development and treatment. With a robust set of qualified biomarkers, disease diagnosis will be quicker, less invasive and more accurate. Moreover, the safety and effectiveness of new therapeutics will be enhanced, drug products will get to patients in less time and treatment decisions will be tailored more effectively to the needs of each patient. In short, MBI is at the forefront of personalized medicine.
MBI is currently focused on developing biomarkers for lymphoma and leukemia through its Hematological Cancer Profiling System™, and for cardiovascular disease through its Cardiovascular Disease Profiling System™.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer